Trial · NCT01741545
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved Sustained Virologic Response (SVR12) at Follow-Up Week 12 | Cohort A | 91.7 | 95% Confidence Interval 61.5 to 99.8 | Percentage of participants | |
| Percentage of Participants Who Achieved Sustained Virologic Response (SVR12) at Follow-Up Week 12 | Cohort B | 89.7 | 95% Confidence Interval 75.8 to 97.1 | Percentage of participants | |
| Percentage of Participants With Rapid Virologic Response (RVR) | Cohort A | 91.7 | 95% Confidence Interval 61.5 to 99.8 | Percentage of participants | |
| Percentage of Participants With Rapid Virologic Response (RVR) | Cohort B | 76.9 | 95% Confidence Interval 60.7 to 88.9 | Percentage of participants | |
| Percentage of Participants With Complete Early Virologic Response (cEVR) | Cohort A | 91.7 | 95% Confidence Interval 61.5 to 99.8 | Percentage of participants | |
| Percentage of Participants With Complete Early Virologic Response (cEVR) | Cohort B | 92.3 | 95% Confidence Interval 79.1 to 98.4 | Percentage of participants | |
| Percentage of Participants With End of the Treatment Response (EOTR) | Cohort A | 100 | 95% Confidence Interval 73.5 to 100 | Percentage of participants | |
| Percentage of Participants With End of the Treatment Response (EOTR) | Cohort B | 100 | 95% Confidence Interval 91 to 100 | Percentage of participants | |
| Percentage of Participants With Sustained Virologic Response at Follow-Up Week 24 (SVR24) | Cohort A | 66.7 | 95% Confidence Interval 34.9 to 90.1 | Percentage of participants | |
| Percentage of Participants With Sustained Virologic Response at Follow-Up Week 24 (SVR24) | Cohort B | 30.8 | 95% Confidence Interval 17 to 47.6 | Percentage of participants | |
| Percentage of Participants With Treatment-Emergent Cytopenic Abnormalities On-Treatment | Cohort A | 0 | 95% Confidence Interval 0 to 26.5 | Percentage of participants | |
| Percentage of Participants With Treatment-Emergent Cytopenic Abnormalities On-Treatment | Cohort B | 0 | 95% Confidence Interval 0 to 9 | Percentage of participants | |
| Percentage of Participants With Flu-Like Symptoms and Musculoskeletal Symptoms On-Treatment | Cohort A | Flu-like symptoms | 8.3 | 95% Confidence Interval 0.2 to 38.5 | Percentage of participants |
| Percentage of Participants With Flu-Like Symptoms and Musculoskeletal Symptoms On-Treatment | Cohort B | Flu-like symptoms | 12.8 | 95% Confidence Interval 4.3 to 27.4 | Percentage of participants |
| Percentage of Participants With Flu-Like Symptoms and Musculoskeletal Symptoms On-Treatment | Cohort A | Musculoskeletal symptoms | 0 | 95% Confidence Interval 0 to 26.5 | Percentage of participants |
| Percentage of Participants With Flu-Like Symptoms and Musculoskeletal Symptoms On-Treatment | Cohort B | Musculoskeletal symptoms | 15.4 | 95% Confidence Interval 5.9 to 30.5 | Percentage of participants |
| Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Dose Reductions, And Death | Cohort A | AEs on treatment | 10 | Percentage of participants | |
| Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Dose Reductions, And Death | Cohort B | AEs on treatment | 38 | Percentage of participants | |
| Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Dose Reductions, And Death | Cohort A | SAEs | 0 | Percentage of participants | |
| Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Dose Reductions, And Death | Cohort B | SAEs | 4 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01741545/results